Rafferty Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.7M | Buy |
|
|||||
|
2025
Q1 | $1.9M | Buy |
|
|||||
|
2024
Q4 | $1.77M | Sell |
|
|||||
|
2024
Q3 | $2.82M | Sell |
|
|||||
|
2024
Q2 | $2.88M | Sell |
|
|||||
|
2024
Q1 | $7.97M | Buy |
|
|||||
|
2023
Q4 | $5.72M | Buy |
|
|||||
|
2023
Q3 | $5.72M | Sell |
|
|||||
|
2023
Q2 | $6.86M | Buy |
|
|||||
|
2023
Q1 | $6.84M | Buy |
|
|||||
|
2022
Q4 | $8.82M | Buy |
|
|||||
|
2022
Q3 | $6.49M | Buy |
|
|||||
|
2022
Q2 | $4.1M | Buy |
|
|||||
|
2022
Q1 | $5.39M | Sell |
|
|||||
|
2021
Q4 | $6.27M | Buy |
|
|||||
|
2021
Q3 | $2.95M | Buy |
|
|||||
|
2021
Q2 | $2.47M | Sell |
|
|||||
|
2021
Q1 | $2.68M | Buy |
|
|||||
|
2020
Q4 | $837K | Sell |
|
|||||
|
2020
Q3 | $1.81M | Buy |
|
|||||
|
2020
Q2 | $1.06M | Buy |
|
|||||
|
2020
Q1 | $34K | Sell |
|
|||||
|
2019
Q4 | $504K | Sell |
|
|||||
|
2019
Q3 | $777K | Sell |
|
|||||
|
2019
Q2 | $1.44M | Buy |
|
|||||
|
2019
Q1 | $855K | Buy |
|